Use of the monoclonal antibody WR17, identifying the CD37 gp40–45 Kd antigen complex, in the diagnosis of B‐lymphoid malignancy

Moore, K.; Cooper, S.; Jones, David B.

doi:10.1002/path.1711520103

Cited by 38 publications

(18 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…25) and 1F5 (CD20, mIgG2a; Ref. 26) were produced from the original hybridomas at the Tenovus Research Laboratory (University of Southampton, Southampton, U.K.).…”

Section: Mabs and Ab Constructsmentioning

confidence: 99%

Triggering FCα-Receptor I (CD89) Recruits Neutrophils as Effector Cells for CD20-Directed Antibody Therapy

Stockmeyer

Dechant

Egmond³

et al. 2000

The Journal of Immunology

107

View full text Add to dashboard Cite

CD20 Abs induce clinical responses in lymphoma patients, but there are considerable differences between individual patients. In 51Cr release assays with whole blood as effector source, RAJI cells were effectively killed by a mouse/human chimeric IgG1 construct of CD20 Ab 1F5, whereas ARH-77 proved resistant to killing by this Ab. When whole blood was fractionated into plasma, mononuclear cells, or granulocytic effector cells, RAJI cells were effectively killed in the presence of complement-containing plasma, whereas the mature B cell line ARH-77 proved complement resistant. However, with a bispecific Ab (BsAb) against the myeloid receptor for IgA (CD89; FcαRI) and CD20, a broad range of B cell lines were effectively killed. FcαRI is expressed on monocytes/macrophages, neutrophils, and eosinophils. As the numbers of these effector cells and their functional activity can be enhanced by application of G-CSF or GM-CSF, lysis via (FcαRI × CD20) BsAb was significantly enhanced in blood from patients during therapy with these myeloid growth factors. Interestingly, the major effector cell population for this BsAb were polymorphonuclear neutrophils, which proved ineffective in killing malignant B cells with murine, chimeric IgG1, or FcγRI- or FcγRIII-directed BsAbs against CD20. Experiments with blood from human FcαRI/FcγRI double-transgenic mice showed corresponding results, allowing the establishment of relevant syngenic animal models in these mice. In conclusion, the combination of myeloid growth factors and an (FcαRI × CD20) BsAb may represent a promising approach to improve effector cell recruitment for CD20-directed lymphoma therapy.

show abstract

“…25) and 1F5 (CD20, mIgG2a; Ref. 26) were produced from the original hybridomas at the Tenovus Research Laboratory (University of Southampton, Southampton, U.K.).…”

Section: Mabs and Ab Constructsmentioning

confidence: 99%

Triggering FCα-Receptor I (CD89) Recruits Neutrophils as Effector Cells for CD20-Directed Antibody Therapy

Stockmeyer

Dechant

Egmond³

et al. 2000

The Journal of Immunology

107

View full text Add to dashboard Cite

show abstract

“…1 However, CD37 is highly expressed on malignant B cells in nonHodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). 1,7,8 This expression profile suggests that CD37 represents a promising therapeutic target for B-cell malignancies.…”

Section: Introductionmentioning

confidence: 99%

A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies

Deckert

Park

Chicklas

et al. 2013

Blood

View full text Add to dashboard Cite

show abstract

“…With respect to cancer, CD37 is highly expressed on malignant B cells in non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL; ref. 6). Consequently, CD37 represents a promising therapeutic target for B-cell malignancies.…”

Section: Introductionmentioning

confidence: 99%

AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody–Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML

Pereira

Guevara

Jin

et al. 2015

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

CD37 is a tetraspanin expressed on malignant B cells. Recently, CD37 has gained interest as a therapeutic target. We developed AGS67E, an antibody–drug conjugate that targets CD37 for the potential treatment of B/T-cell malignancies. It is a fully human monoclonal IgG2 antibody (AGS67C) conjugated, via a protease-cleavable linker, to the microtubule-disrupting agent mono-methyl auristatin E (MMAE). AGS67E induces potent cytotoxicity, apoptosis, and cell-cycle alterations in many non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) cell lines and patient-derived samples in vitro. It also shows potent antitumor activity in NHL and CLL xenografts, including Rituxan-refractory models. During profiling studies to confirm the reported expression of CD37 in normal tissues and B-cell malignancies, we made the novel discovery that the CD37 protein was expressed in T-cell lymphomas and in AML. AGS67E bound to >80% of NHL and T-cell lymphomas, 100% of CLL and 100% of AML patient-derived samples, including CD34+CD38− leukemic stem cells. It also induced cytotoxicity, apoptosis, and cell-cycle alterations in AML cell lines and antitumor efficacy in orthotopic AML xenografts. Taken together, this study shows not only that AGS67E may serve as a potential therapeutic for B/T-cell malignancies, but it also demonstrates, for the first time, that CD37 is well expressed and a potential drug target in AML.

show abstract

Use of the monoclonal antibody WR17, identifying the CD37 gp40–45 Kd antigen complex, in the diagnosis of B‐lymphoid malignancy

Cited by 38 publications

References 22 publications

Triggering FCα-Receptor I (CD89) Recruits Neutrophils as Effector Cells for CD20-Directed Antibody Therapy

Triggering FCα-Receptor I (CD89) Recruits Neutrophils as Effector Cells for CD20-Directed Antibody Therapy

A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies

AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody–Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML

Contact Info

Product

Resources

About